Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,826,732 papers from all fields of science
Search
Sign In
Create Free Account
naptumomab estafenatox
A recombinant fusion protein consisting of the antigen-binding fragment of a monoclonal antibody directed towards the tumor-associated oncofetal…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
6 relations
Narrower (1)
ABR-217620
Broader (3)
Enterotoxins
Immunoconjugates
Monoclonal Antibodies
NCIt Antineoplastic Agent Terminology
antigen binding
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis
R. Hawkins
,
M. Gore
,
+13 authors
T. Eisen
Clinical Cancer Research
2016
Corpus ID: 43679886
Purpose: To prospectively determine the efficacy of naptumomab estafenatox (Nap) + IFNα versus IFN in metastatic renal cell…
Expand
2015
2015
Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α
E. Elkord
,
D. Burt
,
A. Sundstedt
,
Ö. Nordle
,
G. Hedlund
,
R. Hawkins
Oncotarget
2015
Corpus ID: 8020411
Naptumomab estafenatox/ABR-217620/ANYARA (Nap) has been evaluated in clinical phase 1 and 2/3 studies. RCC patients in the phase…
Expand
Review
2014
Review
2014
Naptumomab Estafenatox: Targeted Immunotherapy with a Novel Immunotoxin
T. Eisen
,
G. Hedlund
,
G. Forsberg
,
R. Hawkins
Current Oncology Reports
2014
Corpus ID: 10712187
Improvement of cancer therapy by introducing new concepts is still urgent even though there have been major advancements lately…
Expand
Review
2013
Review
2013
Which are the antibodies to watch in 2013?
J. Reichert
mAbs
2013
Corpus ID: 26098193
The start of the new year signals that it is time for mAbs’ annual review of the therapeutic monoclonal antibodies (mAbs) in…
Expand
Review
2013
Review
2013
Antibodies to watch in 2013
J. Reichert
mAbs
2013
Corpus ID: 11874468
The transitions of antibody therapeutics to late-stage clinical development, regulatory review and the market are proceeding at a…
Expand
Review
2011
Review
2011
Antibody-based therapeutics to watch in 2011
J. Reichert
mAbs
2011
Corpus ID: 12626878
This overview of 25 monoclonal antibody (mAb) and 5 Fc fusion protein therapeutics provides brief descriptions of the candidates…
Expand
2010
2010
Naptumomab Estafenatox, an Engineered Antibody-superantigen Fusion Protein With Low Toxicity and Reduced Antigenicity
G. Forsberg
,
N. Skartved
,
+4 authors
T. Nederman
Journal of immunotherapy
2010
Corpus ID: 2103600
Antibody-targeted superantigens have a potential to become useful drugs for tumor therapy. However, clinical practice has…
Expand
Review
2010
Review
2010
Naptumomab estafenatox: a new immunoconjugate
M. Robinson
,
R. Alpaugh
,
H. Borghaei
Expert opinion on biological therapy
2010
Corpus ID: 38098165
Importance of the field: New agents that specifically engage the immune system are being tested in a variety of malignancies…
Expand
Highly Cited
2010
Highly Cited
2010
Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials
M. Tighiouart
,
A. Rogatko
2010
Corpus ID: 88512671
Traditionally, the major objective in phase I trials is to identify a working-dose for subsequent studies, whereas the major…
Expand
Highly Cited
2009
Highly Cited
2009
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung…
H. Borghaei
,
K. Alpaugh
,
+7 authors
R. Cohen
Journal of clinical oncology : official journal…
2009
Corpus ID: 20137959
PURPOSE Two phase I studies were conducted of ABR-217620 alone or in combination with docetaxel. This is a recombinant fusion…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE